Capitalizing on more than three decades of experience as a pharmaceutical executive, John Klein of Alpine, NJ, operates as the chairman of Cambridge Therapeutics. John Klein is also the founder of Bilogix, an enterprise performance management (EPM) solutions provider where he serves as the chairman and CEO.
EPM leverages analytics to improve business performance and efficiency and reduce costs, among other benefits. Despite the obvious benefits of implementing EPM projects, doing so can be a waste of time and resources without the proper planning or technical skills required. Below are three common reasons why an EPM project might fail:
– Lack of technical expertise. Implementing EPM tools requires a high level of technical expertise, and, while most EPM firms boast about their technical competencies, it’s crucial for businesses to ask specific questions about how they will solve their respective problems.
– No clear milestones. Establishing clear milestones and goals for EPM implementation is essential to avoid and resolve potential roadblocks. It can also help to begin with a small set of EPM deliverables as opposed to grandiose goals and objectives.
– Lack of strategic vision. Companies utilizing EPM solutions should have a clear and defined purpose for why they are doing so. Emphasis should be placed on improving overall company performance as opposed to the singular focus of completing financial tasks faster.
The chairman of Cambridge Therapeutics, John Klein is a pharmaceutical industry executive whose newest venture is the Alpine, NJ, based Bilogix. Focused on boosting operational effectiveness, Cambridge Therapeutics head John Klein has developed Bilogix’s next generation enterprise performance management (EPM) platform.
While there are various strategic approaches to EPM, one common approach involves utilizing an analytical framework while working to provide predictive capabilities. Through intuitive scorecards and dashboards, executives are able to view a variety of metrics across several business units that are arranged at various hierarchical levels.
Adhering to rigorous six sigma processes, EPM applications effectively contextualize operational strategy through key performance indicators that quantify results in terms of attaining targets. This approach allows organizational processes to be aligned across functions, with resources actively deployed in areas that will bring about sought after change and transformation.
Within an integrated EPM framework, steps taken to improve the corporate process are disseminated via financial consolidation and management reporting.
John Klein draws upon more than four decades of leadership experience in the pharmaceutical sector to his position as chairman of the Alpine, NJ-based Cambridge Therapeutics. In addition to this role, John Klein serves as the chairman and CEO of Bilogix, LLC, which provides unique enterprise performance management (EPM) solutions to customers in line with their corporate strategy.
EPM services can enhance business strategy and processes such as budgeting and financial modeling and analysis. EPM is a complex methodology that involves a number of aspects, such as the creation of an enterprise strategy. Designed to help companies seeking to improve their performance, EPM requires a solid strategic plan as its basis. Through EPM, the various aspects of the strategic plan are deployed throughout an organization. Another area of EPM entails mapping an organization. A blueprint is created outlining how the work will be accomplished and what the outputs will be.
Mapping an organization aids in the identification of areas in need of improvement and key performance indicators (KPIs). An additional aspect of EPM involves developing scorecards. Business scorecards can provide managers with quick access to critical information. The scorecards show metrics on KPIs that can aid in managerial decision-making.
Based in Alpine, NJ, John Klein is an experienced pharmaceutical executive who has served as the chairman of Cambridge Therapeutics since 2011. Additionally, John Klein is the chairman and CEO of Bilogix, LLC, which operates in the enterprise performance management (EPM) space.
A set of processes and applications that help analyze and predict the performance of an organization, EPM can significantly improve actions and outcomes relating to business strategy, enterprise planning and budgeting, financial modeling, and business reporting. However, in order to increase the likelihood of the success of an EPM project, managers must clearly identify the scope of the project, including its goals and objectives.
All relevant stakeholders should be consulted in determining the work required to achieve the project’s goals. Moreover, it is vital to define what won’t be accomplished during the project to ensure all involved are completing tasks in line with its primary purpose. Setting the project’s scope will also help define the tools required to outline project activities, establish project phases, assign resources, and estimate the budget required to complete the project. Working with stakeholders, managers should then establish a list of desired goals, such as improved performance times or enhanced process efficiencies, which will be used to gauge the success of the project.
Possessing more than two decades of experience in pharmaceutical manufacturing, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. Aside from steering Cambridge Therapeutics, John Klein directs the business-development firm Bilogix.
Providing services in the growing field of enterprise performance management (EPM), Bilogix employs experienced consultants who assist businesses in conducting strategic analyses of their business intelligence (BI) and overall operational efficiency to perform better in a constantly-evolving marketplace.
EPM consultants might also evaluate the company’s expenditures and how much value that spending contributes to or review return on investment (ROI) data. The ROI process provides measurable values for determining an investment’s efficiency or making comparisons between different ones. Additionally, it assesses the return on specific investments in relation to its cost. These practices help to better inform executive management on how to create the best solutions for increasing performance and generating more profit for the enterprise.
Serving as the chairman of Cambridge Therapeutics in Alpine, NJ, John Klein has more than two decades of executive experience in the healthcare and pharmaceutical industries. In addition to leading Cambridge Therapeutics, John Klein recently founded a new firm in Alpine, NJ, called Bilogix.
A company that provides enterprise performance management (EPM) services, Bilogix helps business clients attain maximum efficiency and boost profits. Using a complex approach to operations analysis, the EPM team reviews details such as budgets, sales forecasts and reports, and accounting information to determine ways in which a firm can enhance its performance and eliminate the waste of resources. The goal of EPM is to ensure that businesses have the data and knowledge they need to make optimal operational decisions that promote continued growth and long-term sustainability.
A large part of the EPM analysis deals with a company’s technological capacity. As cloud computing becomes more pervasive, smart institution leaders are adopting this and other advanced technologies to increase their flexibility and stay relevant.
An accomplished pharmaceutical executive with more than 20 years of industry experience, John Klein serves as the chairman of the Alpine, NJ-based Cambridge Therapeutics. In addition to his responsibilities at Cambridge Therapeutics, John Klein actively follows health-related news affecting NJ.
Home healthcare agencies in NJ recently warned of a future shortage of private duty nurses (PDNs) in the state. Pointing to lower-than-desired Medicaid reimbursement rates, agency representative said that they are experiencing difficulties recruiting qualified nurses for home-based services. PDNs provide around-the-clock care for medically complex patients in their homes, sometimes tending to individuals who are cognitively impaired or born with congenital defects.
Licensed as either a registered nurse or a licensed practical nurse, PDNs are paid through Medicaid reimbursements, making it hard for them to earn as much as their hospital-based counterparts. More than a decade has passed since the last Medicaid-reimbursement increase.
According to an internal study by BAYADA Home Health Care, the home healthcare industry attracts only 17 percent of registered nurses and 40 percent of licensed practical nurses, leaving many patients without the nursing care they need.